Table 2.
Classification tasks | Model | Training/Validation cohort | Test cohort | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
AUC | ACC | SEN | SPE | P value | AUC | ACC | SEN | SPE | P value | ||
HR+ vs. HR- | Rss (DWI600) | 0.767 | 0.736 | 0.770 | 0.653 | 0.768 | 0.693 | 0.689 | 0.706 | ||
RFF (DWI600+DWI800+DCE5) | 0.778 | 0.737 | 0.753 | 0.699 | 0.066 | 0.726 | 0.659 | 0.673 | 0.613 | 0.028 | |
TNBC vs. HEBC | Rss (ADC) | 0.769 | 0.656 | 0.667 | 0.650 | 0.718 | 0.692 | 0.684 | 0.700 | ||
RFF(ADC+DCE2+DCE4) | 0.787 | 0.692 | 0.655 | 0.720 | 0.043 | 0.773 | 0.645 | 0.636 | 0.650 | 0.017 | |
TNBC vs. non-TNBC | Rss (ADC) | 0.784 | 0.727 | 0.683 | 0.734 | 0.735 | 0.707 | 0.611 | 0.721 | ||
RFF(ADC+DWI600+T2WI+DCE2) | 0.818 | 0.718 | 0.705 | 0.721 | 0.042 | 0.773 | 0.767 | 0.636 | 0.780 | 0.025 |
P value: compared the performance between the optimal Rss model and the optimal RFF model in the training/validation cohort and test cohort of each discriminative task. Significant values (P < 0.05) are presented in bold. HR, hormone receptor; HEBC: human epidermal growth factor receptor 2 enriched BC; TNBC: triple-negative breast cancer. AUC, area under the receiver-operating characteristic curve; SEN, sensitivity; SPE, specificity; ACC, accuracy.